RGS 0.00% 12.0¢ regeneus ltd

It is the best deal for a ASX listed micro cap biotech I can...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,884 Posts.
    lightbulb Created with Sketch. 2
    It is the best deal for a ASX listed micro cap biotech I can think of in recent memory. Cash up front, non dilutive, 50-50 JV etc.
    RGS are either stunning negotiators or AGC really wanted Progenza - I suspect the latter.
    With an investment of this size AGC are going to want to be proactive getting sub licensing deals etc, and overall getting Progenza to market. Like others here I'm surprised this hasn't moved, but there you go, that's the market.
    Another deal, or any further developments from the JV in Japan will get things moving surely?

    Just an aside, the 21st century Cures Act in the US is likely to be positive for stem cell companies and create a better environment for doing deals. in regenerative medicine more generally.
 
watchlist Created with Sketch. Add RGS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.